138 related articles for article (PubMed ID: 10588226)
1. Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.
Struthers AD; MacFadyen R; Fraser C; Robson J; Morton JJ; Junot C; Ezan E
J Am Coll Cardiol; 1999 Dec; 34(7):2072-7. PubMed ID: 10588226
[TBL] [Abstract][Full Text] [Related]
2. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
3. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.
Farquharson CA; Struthers AD
J Am Coll Cardiol; 2002 Mar; 39(5):767-75. PubMed ID: 11869839
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
5. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
MacFadyen RJ; Lee AF; Morton JJ; Pringle SD; Struthers AD
Heart; 1999 Jul; 82(1):57-61. PubMed ID: 10377310
[TBL] [Abstract][Full Text] [Related]
6. Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus.
Sharman DC; Morris AD; Struthers AD
Diabetologia; 2007 Oct; 50(10):2061-6. PubMed ID: 17676311
[TBL] [Abstract][Full Text] [Related]
7. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.
Jorde UP; Vittorio T; Katz SD; Colombo PC; Latif F; Le Jemtel TH
Circulation; 2002 Aug; 106(9):1055-7. PubMed ID: 12196328
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
Petrie MC; Padmanabhan N; McDonald JE; Hillier C; Connell JM; McMurray JJ
J Am Coll Cardiol; 2001 Mar; 37(4):1056-61. PubMed ID: 11263608
[TBL] [Abstract][Full Text] [Related]
10. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
11. The practical assessment of compliance with ACE-inhibitor therapy--a novel approach.
MacFadyen RJ; Struthers AD
J Cardiovasc Pharmacol; 1997 Jan; 29(1):119-24. PubMed ID: 9007680
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements.
Le Meur Y; Lorgeot V; Comte L; Szelag JC; Aldigier JC; Leroux-Robert C; Praloran V
Am J Kidney Dis; 2001 Sep; 38(3):510-7. PubMed ID: 11532682
[TBL] [Abstract][Full Text] [Related]
13. Urine N-acetyl-Ser-Asp-Lys-Pro measurement as a versatile biomarker to assess adherence to angiotensin-converting enzyme inhibitors.
Kably B; Billaud EM; Derobertmasure A; Blanchard A; Boutouyrie P; Azizi M
J Hypertens; 2022 Feb; 40(2):348-355. PubMed ID: 34508023
[TBL] [Abstract][Full Text] [Related]
14. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
15. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects.
Kawamura M; Imanashi M; Matsushima Y; Ito K; Hiramori K
Clin Exp Pharmacol Physiol; 1992 Aug; 19(8):547-53. PubMed ID: 1326422
[TBL] [Abstract][Full Text] [Related]
16. Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays.
Struthers AD; Anderson G; MacFadyen RJ; Fraser C; MacDonald TM
Heart; 1999 Nov; 82(5):584-8. PubMed ID: 10525514
[TBL] [Abstract][Full Text] [Related]
17. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
18. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
[TBL] [Abstract][Full Text] [Related]
19. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Rieger KJ; Saez-Servent N; Papet MP; Wdzieczak-Bakala J; Morgat JL; Thierry J; Voelter W; Lenfant M
Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):373-8. PubMed ID: 8257427
[TBL] [Abstract][Full Text] [Related]
20. Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.
Seeland U; Kouchi I; Zolk O; Jockenhövel F; Itter G; Linz W; Böhm M
Eur J Heart Fail; 2003 Jun; 5(3):241-6. PubMed ID: 12798820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
